A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

Julie Marie Vose, Amit Panwalkar, Robert Belanger, Bertrand Coiffier, Michele Baccarani, Stephanie Gregory, Thierry Facon, Renato Fanin, Dolores Caballero, Dina Ben-Yehuda, Francis Giles

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Options for patients with relapsed/refractory lymphoproliferative disorders and multiple myeloma are currently limited. Troxacitabine has shown promise in preclinical studies in a variety of malignancies; hence, the current study was conducted to evaluate the activity of troxacitabine in relapsed or refractory lymphoid malignancies. This was a phase II, open-label, multinational, multicenter study of patients with relapsed or refractory lymphoproliferative disorders or multiple myeloma. Thirty-four adults were enrolled in the study and received the study drug at either 5.4 mg/m2 (n=16) or 4.3 mg/m2 (n=18). The dose was decided in a phase I study, during which dose escalation was carried to reach a maximum tolerated dose with an acceptable toxicity profile. Two separate phase I studies were performed in Europe and the US. Troxacitabine was administered by intravenous infusion over 30 min daily for days 1-5 every 4 weeks. Treatment was continued to disease progression or until the subjects met criteria for withdrawal or unacceptable toxicities were evident as outlined in the protocol. Two patients had a partial response (PR) to treatment with troxacitabine to yield an overall response rate of 13%. There were no complete responses seen with the drug. Stable disease was achieved in 15 patients (44%). All patients had at least one treatment related adverse event, which led to six withdrawals from the study. Hematologic toxicity constituted the most common adverse events. Serious adverse effects were seen in 62% of patients. None of the 13 deaths were attributed directly to troxacitabine. As a single agent, troxacitabine has limited benefit in patients with advanced lymphoproliferative disorders or multiple myeloma. Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalLeukemia and Lymphoma
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Multiple Myeloma
Multicenter Studies
Lymphoproliferative Disorders
Neoplasms
Maximum Tolerated Dose
Hematologic Neoplasms
Therapeutics
troxacitabine
Intravenous Infusions
Pharmaceutical Preparations
Disease Progression
Pharmacokinetics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. / Vose, Julie Marie; Panwalkar, Amit; Belanger, Robert; Coiffier, Bertrand; Baccarani, Michele; Gregory, Stephanie; Facon, Thierry; Fanin, Renato; Caballero, Dolores; Ben-Yehuda, Dina; Giles, Francis.

In: Leukemia and Lymphoma, Vol. 48, No. 1, 01.01.2007, p. 39-45.

Research output: Contribution to journalArticle

Vose, JM, Panwalkar, A, Belanger, R, Coiffier, B, Baccarani, M, Gregory, S, Facon, T, Fanin, R, Caballero, D, Ben-Yehuda, D & Giles, F 2007, 'A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma', Leukemia and Lymphoma, vol. 48, no. 1, pp. 39-45. https://doi.org/10.1080/10428190600909578
Vose, Julie Marie ; Panwalkar, Amit ; Belanger, Robert ; Coiffier, Bertrand ; Baccarani, Michele ; Gregory, Stephanie ; Facon, Thierry ; Fanin, Renato ; Caballero, Dolores ; Ben-Yehuda, Dina ; Giles, Francis. / A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 1. pp. 39-45.
@article{ba2c68aefc2e4ddfb0b7f71fe31d9947,
title = "A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma",
abstract = "Options for patients with relapsed/refractory lymphoproliferative disorders and multiple myeloma are currently limited. Troxacitabine has shown promise in preclinical studies in a variety of malignancies; hence, the current study was conducted to evaluate the activity of troxacitabine in relapsed or refractory lymphoid malignancies. This was a phase II, open-label, multinational, multicenter study of patients with relapsed or refractory lymphoproliferative disorders or multiple myeloma. Thirty-four adults were enrolled in the study and received the study drug at either 5.4 mg/m2 (n=16) or 4.3 mg/m2 (n=18). The dose was decided in a phase I study, during which dose escalation was carried to reach a maximum tolerated dose with an acceptable toxicity profile. Two separate phase I studies were performed in Europe and the US. Troxacitabine was administered by intravenous infusion over 30 min daily for days 1-5 every 4 weeks. Treatment was continued to disease progression or until the subjects met criteria for withdrawal or unacceptable toxicities were evident as outlined in the protocol. Two patients had a partial response (PR) to treatment with troxacitabine to yield an overall response rate of 13{\%}. There were no complete responses seen with the drug. Stable disease was achieved in 15 patients (44{\%}). All patients had at least one treatment related adverse event, which led to six withdrawals from the study. Hematologic toxicity constituted the most common adverse events. Serious adverse effects were seen in 62{\%} of patients. None of the 13 deaths were attributed directly to troxacitabine. As a single agent, troxacitabine has limited benefit in patients with advanced lymphoproliferative disorders or multiple myeloma. Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies.",
author = "Vose, {Julie Marie} and Amit Panwalkar and Robert Belanger and Bertrand Coiffier and Michele Baccarani and Stephanie Gregory and Thierry Facon and Renato Fanin and Dolores Caballero and Dina Ben-Yehuda and Francis Giles",
year = "2007",
month = "1",
day = "1",
doi = "10.1080/10428190600909578",
language = "English (US)",
volume = "48",
pages = "39--45",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

AU - Vose, Julie Marie

AU - Panwalkar, Amit

AU - Belanger, Robert

AU - Coiffier, Bertrand

AU - Baccarani, Michele

AU - Gregory, Stephanie

AU - Facon, Thierry

AU - Fanin, Renato

AU - Caballero, Dolores

AU - Ben-Yehuda, Dina

AU - Giles, Francis

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Options for patients with relapsed/refractory lymphoproliferative disorders and multiple myeloma are currently limited. Troxacitabine has shown promise in preclinical studies in a variety of malignancies; hence, the current study was conducted to evaluate the activity of troxacitabine in relapsed or refractory lymphoid malignancies. This was a phase II, open-label, multinational, multicenter study of patients with relapsed or refractory lymphoproliferative disorders or multiple myeloma. Thirty-four adults were enrolled in the study and received the study drug at either 5.4 mg/m2 (n=16) or 4.3 mg/m2 (n=18). The dose was decided in a phase I study, during which dose escalation was carried to reach a maximum tolerated dose with an acceptable toxicity profile. Two separate phase I studies were performed in Europe and the US. Troxacitabine was administered by intravenous infusion over 30 min daily for days 1-5 every 4 weeks. Treatment was continued to disease progression or until the subjects met criteria for withdrawal or unacceptable toxicities were evident as outlined in the protocol. Two patients had a partial response (PR) to treatment with troxacitabine to yield an overall response rate of 13%. There were no complete responses seen with the drug. Stable disease was achieved in 15 patients (44%). All patients had at least one treatment related adverse event, which led to six withdrawals from the study. Hematologic toxicity constituted the most common adverse events. Serious adverse effects were seen in 62% of patients. None of the 13 deaths were attributed directly to troxacitabine. As a single agent, troxacitabine has limited benefit in patients with advanced lymphoproliferative disorders or multiple myeloma. Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies.

AB - Options for patients with relapsed/refractory lymphoproliferative disorders and multiple myeloma are currently limited. Troxacitabine has shown promise in preclinical studies in a variety of malignancies; hence, the current study was conducted to evaluate the activity of troxacitabine in relapsed or refractory lymphoid malignancies. This was a phase II, open-label, multinational, multicenter study of patients with relapsed or refractory lymphoproliferative disorders or multiple myeloma. Thirty-four adults were enrolled in the study and received the study drug at either 5.4 mg/m2 (n=16) or 4.3 mg/m2 (n=18). The dose was decided in a phase I study, during which dose escalation was carried to reach a maximum tolerated dose with an acceptable toxicity profile. Two separate phase I studies were performed in Europe and the US. Troxacitabine was administered by intravenous infusion over 30 min daily for days 1-5 every 4 weeks. Treatment was continued to disease progression or until the subjects met criteria for withdrawal or unacceptable toxicities were evident as outlined in the protocol. Two patients had a partial response (PR) to treatment with troxacitabine to yield an overall response rate of 13%. There were no complete responses seen with the drug. Stable disease was achieved in 15 patients (44%). All patients had at least one treatment related adverse event, which led to six withdrawals from the study. Hematologic toxicity constituted the most common adverse events. Serious adverse effects were seen in 62% of patients. None of the 13 deaths were attributed directly to troxacitabine. As a single agent, troxacitabine has limited benefit in patients with advanced lymphoproliferative disorders or multiple myeloma. Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=34247211114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247211114&partnerID=8YFLogxK

U2 - 10.1080/10428190600909578

DO - 10.1080/10428190600909578

M3 - Article

C2 - 17325846

AN - SCOPUS:34247211114

VL - 48

SP - 39

EP - 45

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -